> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Voucher Used for Vyvgart Hytrulo sNDA
- URL: https://www.fdaweb.com/priority-voucher-used-for-vyvgart-hytrulo-snda/
- Published: 2024-07-16T12:00:00.000Z
- Updated: 2026-09-14T14:35:37.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5157357

*Federal Register* notice: FDA is announcing that Argenx’s supplemental NDA for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), indicated for treating chronic inflammatory demyelinating polyneuropathy, was approved 6/21 using a priority review voucher. Previously, the drug was approved for treating generalized myasthenia gravis. To view the notice, click [here](https://public-inspection.federalregister.gov/2024-15695.pdf?ref=fdaweb.com).